<DOC>
	<DOCNO>NCT00998010</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving bortezomib together temozolomide radiation therapy may kill tumor cell allow doctor save part body cancer start . PURPOSE : This phase II trial study side effect well bortezomib work give together temozolomide regional radiation therapy treat patient newly diagnose glioblastoma multiforme gliosarcoma .</brief_summary>
	<brief_title>Bortezomib , Temozolomide , Regional Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme Gliosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate overall survival 2 year patient newly diagnose glioblastoma multiforme treat bortezomib combination temozolomide regional radiotherapy follow maintenance therapy comprise bortezomib temozolomide . Secondary - Investigate safety tolerability regimen patient . - Determine molecular characterization tumor tissue correlate finding response . OUTLINE : This multicenter study . - Adjuvant chemotherapy : Patients receive bortezomib IV day 1 , 4 , 8 , 11 , 29 , 32 , 36 , 39 oral temozolomide day 1-42 . Patients undergo external-beam fractionate regional radiotherapy 5 day week 6 week absence disease progression unacceptable toxicity . - Maintenance : Beginning 2-6 week radiotherapy , patient receive bortezomib IV day 1 , 4 , 8 , 11 oral temozolomide day 1-5 . Treatment repeat every 28 day 24 course absence disease progression unacceptable toxicity . Tumor tissue sample collect baseline ( surgery ) periodically study analysis . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Must &gt; 18 year old , life expectancy &gt; 8 week Histologically confirm intracranial glioblastoma multiforme ( GBM ) gliosarcoma Must submit unstained paraffin block slide surgical procedure Patients without prior treatment prior diagnosis lowergrade glioma upgraded GBM repeat resection allow At least 21 day since cranial MRI contrast CT scan OR ≥ 96 hour since cranial MRI contrast CT scan patient underwent surgical resection Measurable assessable disease Voluntary write informed consent obtain performance study relate procedure part normal medical care . Karnofsky performance status &gt; 60 % WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL ( transfusion allow ) Bilirubin &lt; 2.5 time upper limit normal ( ULN ) SGOT &lt; 2.5 time ULN Creatinine &lt; 1.5 mg/dL Creatinine clearance ≥ 20 mL/minute Serum sodium &gt; 130 mmol/L Negative pregnancy test Fertile patient must use effective contraception Patients EIAED must transition nonEAIED ≥ 2 week Concurrent fulldose warfarin equivalent ( e.g. , unfractionated and/or low molecular weight heparin ) allow peripheral neuropathy ≥ grade 2 Myocardial infarction within past 6 month NYHA class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia active conduction system abnormalities hypersensitivity bortezomib , boron , mannitol serious medical psychiatric illness would interfere study participation include , limited , follow : Ongoing active infection require IV antibiotic Psychiatric illness and/or social situation would limit compliance study requirement Disorders associate significant immunocompromised state ( e.g. , HIV , systemic lupus erythematosus ) history stroke within past 6 month malignancy within past 3 year except completely resect basal cell carcinoma squamous cell carcinoma skin , situ malignancy ( i.e. , cervical cancer ) , lowrisk prostate cancer curative therapy significant medical illness , investigator 's opinion , adequately controlled appropriate therapy would compromise patient 's ability tolerate therapy disease obscure toxicity dangerously alter drug metabolism viral hepatitis ( HBV surface antigen positive ) active hepatitis C infection Prior concurrent corticosteroid , automate external defibrillator , analgesic , drug treat symptom prevent complication allow concurrent investigational drug must stop least 4 month prior therapy . prior radiotherapy brain prior cytotoxic noncytotoxic drug therapy experimental drug therapy ( include chemotherapy , hormonal therapy , immunotherapy ) direct brain tumor prior polifeprosan 20 carmustine implant ( Gliadel wafer ) concurrent stereotactic radiosurgery brachytherapy concurrent sargramostim concurrent inducer CYP450 3A4 ( e.g. , enzymeinducing antiepileptic drug [ EIAED ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>